Claude Y. Cuilleron

Claude Y. Cuilleron

Auto-generated profile, based on publicly available information

Claude Y. Cuilleron

A ISPB-Faculté de Pharmacie , Université de Lyon, Université Lyon 1 , Lyon , France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
GAGhina Alameh
Ghina Alameh
AEAgnès Emptoz-Bonneton
Agnès Emptoz-Bonneton
MRMarc Rolland de Ravel
Marc Rolland de Ravel
EMEva L. Matera
Eva L. Matera
EMElisabeth Mappus
Elisabeth Mappus
CCClaude Y. Cuilleron
Claude Y. Cuilleron
Synthetic progesterone and 5α/β-pregnane-3,20-dione derivatives were evaluated as in vitro and in vivo modulators of multidrug-resistance (MDR) using two P-gp-expressing human cell lines, the non-steroidogenic K562/R7 erythroleukaemia cells and the steroidogenic NCI-H295R adrenocortical carcinoma cells, both resistant to doxorubicin. The maximal effect in both cell lines was observed for 7α-O-benzoyloxy,11α(R)-O-tetrahydropyranyloxy-5β-pregnane-3,20-dione 4. This modulator co-injected with doxorubicin significantly decreased the tumour size and increased the survival time of immunodeficient mice xenografted with NCI-H295R or K562/R7 cells.